Daily News – 16 October 2025
About this episode
Adcytherix raises €105M to advance new ADC oncologics; HyImpulse closes €45M for SL1 hybrid launch vehicle and satellite transport services; the EIB supports a "28th regime" to simplify EU rules and support scaleups and cross-border fundraising. This episode's main theme is startup funding. Central thesis: Adcytherix and HyImpulse raise significant funds for innovation in oncology and transportation. What are we specifically covering? Adcytherix is a startup focusing on developing new antibody-drug conjugates (ADC) for cancer treatment. HyImpulse is a company developing a hybrid launch vehicle for satellite transport. European perspective: Fundraising and EIB support are crucial for European startups, as they can accelerate innovation and competitiveness in the global market. Strategic implications: Simplification of EU rules to support startup growth. Key players: Adcytherix, HyImpulse, EIB.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Main news
Startups mentioned
Adcytherix
Adcytherix is a biopharmaceutical company based in Marseille developing next-generation ADCs with innovative payloads for tumours with high unmet therapeutic need.
HyImpulse
HyImpulse developed paraffin-based hybrid propulsion engines — a safer, cheaper and more regenerable propellant vs traditional solid and liquid propellants — for the SR75 suborbital rocket and the upcoming SL1 orbital rocket with 600 kg payload capacity.
Why they matter
Semplificazione delle regole UE per favorire la crescita delle startup.